FindTrial
Sign In

Rituximab and Lenalidomide

DRUG3 trials

Sponsors

Arbeitsgemeinschaft medikamentoese Tumortherapie, Genmab

Conditions

Diffuse Large B Cell LymphomaDiffuse Large B-Cell LymphomaFollicular LymphomaHigh-grade B-cell LymphomaLymphoma of the Mucosa Associated Lymphoid Tissue (MALT)Marginal Zone LymphomaPrimary Mediastinal Large B Cell LymphomaSmall Lymphocytic Lymphoma

Phase 1

Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)
Active, not recruitingNCT04542824
GenmabDiffuse Large B Cell Lymphoma, Follicular Lymphoma, High-grade B-cell Lymphoma +3
Start: 2020-08-20End: 2027-09-01Updated: 2026-09-09
Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)
Active, not recruitingNCT04663347
GenmabDiffuse Large B-Cell Lymphoma, Follicular Lymphoma
Start: 2020-11-03End: 2027-09-30Updated: 2026-09-09
Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)
Active, not recruitingNCT04663347
GenmabDiffuse Large B-Cell Lymphoma, Follicular Lymphoma
Start: 2020-11-03End: 2027-09-30Updated: 2026-09-09

Phase 2

Rituximab Plus Lenalidomide in Patients With Mucosa Associated Lymphoid Tissue
CompletedNCT01611259
Arbeitsgemeinschaft medikamentoese TumortherapieLymphoma of the Mucosa Associated Lymphoid Tissue (MALT)
Start: 2012-05-31End: 2015-02-28Updated: 2017-11-06

Related Papers

Epcoritamab with rituximab and lenalidomide as first-line treatment for follicular lymphoma (EPCORE NHL-2): an open-label, multicentre, phase 1/2 b trial
The Lancet Haematology2026-08-28
First-line treatment with epcoritamab in combination with bendamustine plus rituximab induces sustained remissions beyond 3 years in patients with follicular lymphoma.
2026-08-04
Exposure–Response Analyses to Inform the Optimal Epcoritamab Monotherapy Dosing Regimen in Relapsed or Refractory Follicular Lymphoma
Clinical Pharmacokinetics2026-08-01
Epcoritamab Step-Up Dosing Regimen Selection and Optimization Using Repeated Time-to-Event Modeling for Cytokine Release Syndrome Risk Mitigation.
2026-07-07
Comparison of epcoritamab, lenalidomide, and rituximab versus usual care in relapsed/refractory follicular lymphoma.
2026-07-07
Epcoritamab (epcor) + chemoimmunotherapy (CIT) in patients (pts) with relapsed/refractory large B-cell lymphoma (R/R LBCL) eligible for autologous stem cell transplant (ASCT): Pooled results from arms 4 and 10 of EPCORE NHL-2.
Journal of Clinical Oncology2026-05-27
Epcoritamab plus rituximab, dexamethasone, cytarabine, oxaliplatin/carboplatin induces deep and durable responses in transplant-eligible patients with relapsed or refractory diffuse large B-cell lymphoma: results from the EPCORE NHL-2 trial.
2026-03-05
Three-year follow-up of epcoritamab therapy in Japanese patients with relapsed/refractory follicular lymphoma in EPCORE NHL-3.
2026-01-18
Epcoritamab + R-mini-CHOP results in 2-year remissions and high MRD negativity rates in elderly patients with newly diagnosed DLBCL: Results from the EPCORE NHL-2 trial
Blood2025-11-031 citations
Fixed-duration epcoritamab monotherapy induces high response and MRD-negativity rates in elderly patients with newly diagnosed large B-cell lymphoma (LBCL) and comorbidities: Results from EPCORE DLBCL-3
Blood2025-11-031 citations
Fixed-duration epcoritamab + R-CHOP in patients with newly diagnosed DLBCL and high IPI scores (3–5) led to sustained remissions and disease-free survival beyond 3 years: Results from the EPCORE NHL-2 trial
Blood2025-11-031 citations
Fixed-duration epcoritamab in combination with bendamustine + Rituximab (BR) for first-line (1L) treatment of follicular lymphoma (FL): 3-year results from EPCORE NHL-2 arm 3 demonstrate deep and durable responses with manageable safety
Blood2025-11-03
Cytotoxic CD8⁺ T cells are required for CD20xCD3 bispecific antibody-mediated tumor control in B-cell non-Hodgkin lymphomas
Blood2025-11-03
Epcoritamab + GemOx achieves durable >2-year remissions in relapsed/refractory (R/R) 2L+ diffuse large B-cell lymphoma (DLBCL): Long-term data reinforce clinical potential of the regimen across a diverse patient population
Blood2025-11-03
Phase II investigator-initiated trial of epcoritamab-lenalidomide in treatment naïve follicular lymphoma
Blood2025-11-03
Epcoritamab with rituximab + lenalidomide (R2) and epcoritamab maintenance deliver deep and durable remissions in previously untreated (1L) follicular lymphoma (FL): 3-year outcomes from epcore NHL-2 arms 6 and 7
Blood2025-11-03
EPCORE FL-2 Phase 3 trial of epcoritamab with rituximab and lenalidomide (R2) vs chemoimmunotherapy (CIT) in previously untreated follicular lymphoma (FL): Trial in progress
Blood2025-11-03
Fixed-duration epcoritamab plus R2 drives favorable outcomes in relapsed or refractory follicular lymphoma.
2025-11-01
Epcoritamab Plus Gemcitabine and Oxaliplatin Versus Rituximab Plus Gemcitabine and Oxaliplatin in Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Match-Adjusted Comparative Analysis.
2025-10-13
Subcutaneous epcoritamab monotherapy in Japanese patients with relapsed or refractory follicular lymphoma: primary results of the EPCORE NHL-3 trial
Leukemia & lymphoma/Leukemia and lymphoma2025-07-091 citations

50 more papers not shown